Studying gut health in advanced liver cancer patients on immunotherapy
Part of Cancer, Digestive system clinical trials.
This study looks at how the gut microbiome affects treatment response in patients with advanced liver cancer who are receiving immunotherapy. It involves a colonoscopy to collect samples and may help improve future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have advanced liver cancer that cannot be removed with surgery
- You are currently being treated with an immunotherapy drug
- You sign a consent form to participate
- You do not have chronic intestinal diseases like inflammatory bowel disease or celiac disease
- You have not taken antibiotics in the last 4 to 6 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people with advanced liver cancer who are starting a new type of treatment that combines targeted therapy to block blood vessel growth and immune therapy to help your body fight the cancer. It looks at how gut bacteria might affect treatment response.
This trial tests how a combination of targeted therapy (TKI) and immunotherapy (ICI) affects the gut bacteria in people with advanced liver cancer that cannot be surgically removed. It aims to see if changes in the microbiome can help predict treatment response.
This trial tests whether changing the bacteria in your gut (with a probiotic) can help your current immunotherapy work better if your liver cancer has been growing. It's for people with advanced liver cancer who will continue their same immunotherapy despite the cancer progressing.
This trial tests how gut bacteria affect liver cancer treatment. It is for people whose liver cancer worsened after certain targeted and immunotherapy drugs.
This trial tests whether transplanting healthy stool bacteria into your gut can help your own immune system fight liver cancer that has stopped responding to the standard first combination treatment (atezolizumab + bevacizumab). It is for patients whose liver cancer has started growing quickly despite that treatment.
This study looks at how your immune cells respond to two specific immunotherapy-based treatments for advanced liver cancer. Researchers want to understand why some patients respond well and others do not, which could help improve future care.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.